Overview
Thymosin Beta-4 is a 43-amino acid endogenous protein ubiquitously expressed in mammalian tissues, encoded by the TMSB4X gene. It is distinct from TB-500, which is a shorter synthetic heptapeptide fragment derived from its actin-binding domain. TB4 plays a fundamental role in actin dynamics, tissue repair, cardiac regeneration, and immune modulation, with research applications spanning wound healing, cardiac injury, and neurological recovery.
Mechanism of action
Thymosin Beta-4 functions through several coordinated mechanisms. Its primary structural role is G-actin sequestration — TB4 binds globular actin monomers, preventing uncontrolled polymerization and regulating the dynamic equilibrium between G-actin and F-actin required for cell motility and structural integrity. Beyond actin dynamics, TB4 acts extracellularly to promote cell migration, angiogenesis, and stem cell maturation. It upregulates integrin-linked kinase (ILK) expression, activating downstream Akt and PI3K signaling that drives cardiomyocyte survival, reduces apoptosis, and promotes progenitor cell recruitment to sites of injury. Anti-inflammatory effects include downregulation of NF-κB signaling and reduction of pro-inflammatory cytokine production including TNF-α and IL-1β. In cardiac injury models, TB4 mobilizes epicardial progenitor cells and promotes their differentiation into cardiomyocytes, positioning it uniquely among peptides studied for cardiac regeneration.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| Wound healing / tissue repair | subcutaneous | 2–5 mg | twice weekly | Loading phase: 2–5 mg twice weekly for 4–6 weeks. Maintenance: 2–6 mg per month. Do not use more than 3 months without cycling (3 months on, 6 weeks off). |
| Cardiac / systemic regenerative research | intramuscular | 2–5 mg | twice weekly | Protocols mirror subcutaneous administration. Clinical trial dosing has ranged from 0.03–0.3 mg/kg intravenously. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Preclinical research spanning over two decades demonstrates TB4 accelerates healing of dermal wounds, burns, and corneal injuries in rodent and rabbit models, with efficacy confirmed in diabetic and aged animals. Cardiac studies show improved post-MI functional recovery and reduced infarct size. A Phase 2 clinical trial (NCT00832091) evaluated intravenous TB4 in venous stasis ulcers. While the full protein (TB4) remains in earlier clinical stages than its fragment TB-500, its broader mechanistic profile — particularly cardiac progenitor mobilization — distinguishes it as a unique research target. No large-scale human efficacy trials have been completed as of 2026.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Thymosin Beta-4 for synergistic effects.
Legal status
Thymosin Beta-4 (full protein) is subject to the same FDA compounding ban framework that covers TB-500, as a peptide exceeding 40 amino acids. One of 14 peptides under FDA reclassification review (RFK Jr. initiative, 2025–2026). Availability from US compounding pharmacies is restricted; research supply chains remain active.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings. Supplier listings will be available if FDA reclassification is formalized.